'생명윤리및안전에관한법률'의 분석
김장한 · 생명윤리 · 2004
Bioethics and Biosafety Act was enacted in 2004.1.29. and will be in effect from 2005.1.1. except the inhibition of human cloning (article 11), the inhibition of implementation of different species (article 12) and its punishment clauses which were in effect immediately after enactment. This act is composed 9 chapters and 55 articles. In general rules (chapter 1), the aim, definitions, obligations and the principle of self determination are described. In ethical committee (chapter 2), the national and institutional review board have a ground to be founded. In embryonal research (chapter 3), human reproductive cloning is prohibited but the research on residual human embryo and therapeutic cloning using somatic cell nuclear transfer (SCNT) is permitted. Severe ethical debates were raised against this legislation. In genetic examination(chapter 4), the protection of genetic privacy, informed consent and withdrawal, access to and call for research records, request to abolish the genetic material is well equipped. But discrimination in favor of public sector is considered to violate the equal protection (article 24). In protection and use of genetic information (chapter 5), the discrimination due to the genetic difference is prohibited. The gene banking is permitted and the genetic information offer is allowed under the permission of institutional review board and should be noticed to the ministry of Health and Welfare. Personal information should be excluded from the genetic information offer. If medical documents are issued other than patient, genetic information should not be included. In gene therapy (chapter 6), for the treatment of life threatening disease or if the benefit of gene therapy overwhelms that of other therapy or officially determined disease for treatment or prevention, gene therapy is allowed. But the sperm, egg, embryo and fetus could not be objects of gene therapy (article 36). This act will function as general principles of biomedical researches. But ethical debates are still on going and spread widely. The main debates are the allowance of human embryonal research and SCNT therapeutic cloning. Along with that, stem cell research including the use of fetal tissue, maternal protection will be the next themes to be discussed. Still we don't have any regulations. The genetic information as a common property of all mankind, we have to find a way to use it in a fair. Gene therapy could have effect beyond the generations, so the safety and quality of therapeutics is to be guaranteed. The proportions and authority of national and institutional ethical board should be adjusted for well¬functioning. We take a first step to regulate the bioethical and biosafety problems. More efforts will be needed to solve these problems.
Cited by 0 works.